Celularity Inc. (CELU)
NASDAQ: CELU · Real-Time Price · USD
1.520
-0.150 (-8.98%)
At close: May 12, 2025, 4:00 PM
1.580
+0.060 (3.94%)
After-hours: May 12, 2025, 5:49 PM EDT
Celularity Revenue
In the year 2024, Celularity had annual revenue of $54.22M with 138.11% growth. Celularity had revenue of $18.13M in the quarter ending December 31, 2024, with 49.70% growth.
Revenue (ttm)
$54.22M
Revenue Growth
+138.11%
P/S Ratio
0.61
Revenue / Employee
$451,833
Employees
120
Market Cap
34.18M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
CELU News
- 3 days ago - Celularity Announces Full Year 2024 Operating and Financial Results - GlobeNewsWire
- 17 days ago - Celularity Receives Nasdaq Notice Regarding Non-Payment of Nasdaq Fees - GlobeNewsWire
- 4 weeks ago - Celularity Welcomes CMS Action on Medicare Local Coverage Determination for Skin Substitutes Products - GlobeNewsWire
- 2 months ago - Celularity Receives FDA Tissue Reference Group Recommendation Letters for its Natalin and Acelagraft™ Wound Care Products - GlobeNewsWire
- 2 months ago - Celularity Enters Strategic Collaboration Agreement with Clinical Stage Cell Therapy Company - GlobeNewsWire
- 5 months ago - Celularity Inc. Announces Resolution of Nasdaq Listing Compliance Matter - GlobeNewsWire
- 5 months ago - Celularity Reports Over Sevenfold Growth in Net Product Sales through Third Quarter 2024 Compared to Third Quarter 2023 - GlobeNewsWire
- 5 months ago - Celularity Inc. Announces Receipt of Nasdaq Notification - GlobeNewsWire